Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,16
KB10451,26
PKN85,0285,1-0,99
Msft500,62500,68-0,57
Nokia4,3554,4990,53
IBM287,32287,47-0,95
Mercedes-Benz Group AG53,0653,081,63
PFE25,8825,891,29
10.07.2025 19:11:46
Indexy online
AD Index online
select
AD Index online
 

  • 10.07.2025 19:11:08
Supernus (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
33,77 3,37 1,10 257 234
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.07.2025
Popis společnosti
Obecné informace
Název společnostiSupernus Pharmaceuticals Inc
TickerSUPN
Kmenové akcie:Ordinary Shares
RICSUPN.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 674
Akcie v oběhu k 22.04.2025 55 989 623
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice9715 Key West Avenue
MěstoROCKVILLE
PSČ20850
ZeměUnited States
Kontatní osobaPeter Vozzo
Funkce kontaktní osobyInvestor Relations
Telefon13 018 382 500
Fax13026365454
Kontatní telefon14 432 130 505

Business Summary: Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is also developing a range of novel CNS product candidates, including new potential treatments for epilepsy, depression, and other CNS disorders. Its commercial products include Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Supernus Pharmaceuticals Inc revenues increased 4% to $149.8M. Net loss totaled $11.8M vs. income of $124K. Revenues reflect Net product sales-Qelbree segment increase of 44% to $64.7M, Net product sales - GOCOVRI segment increase of 16% to $30.7M. Net loss reflects Contingent consideration loss (gain) increase from $1.1M (income) to $7.7M (expense).
Odvětvová klasifikace
TRBC2012Proprietary & Advanced Pharmaceuticals
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICPharmaceutical Preparations



  • Poslední aktualizace: 10.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Secretary, DirectorJack Khattar6301.01.2005
Chief Financial Officer, Senior Vice PresidentTimothy Dec6623.08.202123.08.2021
Senior Vice President - Intellectual Property, Chief Scientific OfficerPadmanabh Bhatt6701.01.2005
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory AffairsFrank Mottola53
Senior Vice President, Chief Medical Officer - Research and DevelopmentJonathan Rubin63